ASHP therapeutic position statement on strategies for identifying and preventing pneumococcal resistance

Am J Health Syst Pharm. 2014 Mar 1;71(5):417-24. doi: 10.2146/ajhp130514.

Abstract

The incidence of MDRSP continues to increase, causing significant morbidity and mortality. Health care providers should seize the opportunity to promote the judicious use of antimicrobials and vaccinate patients with the pneumococcal vaccines as a means to lessen this significant health problem. Pharmacists are poised to play a key role in patient care by assessing for the need and administering vaccines in compliance with the current guidelines. A pharmacist should have a key role on the antimicrobial stewardship team.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Drug Resistance, Bacterial* / genetics
  • Humans
  • Microbial Sensitivity Tests
  • Pharmacists
  • Pneumococcal Infections / drug therapy*
  • Pneumococcal Infections / epidemiology
  • Pneumococcal Infections / microbiology*
  • Pneumococcal Vaccines / therapeutic use
  • Public Health Surveillance
  • Risk Assessment
  • Societies, Pharmaceutical
  • Streptococcus pneumoniae / drug effects*
  • Streptococcus pneumoniae / genetics
  • Vaccination

Substances

  • Anti-Bacterial Agents
  • Pneumococcal Vaccines